LAVAL, Quebec, Dec. 5, 2011 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti) (TSX-V:APO), a subsidiary of Neptune Technologies & Bioressources Inc. (Neptune), announces the extension of its clinical development program by enrolling the first patients in its second phase II clinical trial designed to assess the safety, efficacy and dose response of its prescription drug candidate, CaPre®, for patients with hypertriglyceridemia.
